Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZ-002 in Metastatic Pancreatic Adenocarcinoma
NCT07344220Phase 2Enrolling by invitation
- Sponsor
- Hoag Memorial Hospital Presbyterian
- Start
- Mar 2026
- Primary completion
- Nov 2028
- Modality
- Antibody-Drug Conjugates (ADCs), Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of DZ-002 in pancreatic adenocarcinoma (PDAC), sponsored by Hoag Memorial Hospital Presbyterian. Started Mar 2026; status: enrolling by invitation.
02
Drugs
DZ-002
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07344220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07344220.